301103.SZ
何氏眼科
SZSE · Q 卫生 · CN
CNY 16.39
−2.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 1.1B | 1.2B | 955.3M |
| Cost of Revenue | 651.1M | 644.8M | 672.6M | 690.3M | 588.5M |
| Gross Profit | 455.2M | 447.8M | 423.0M | 494.9M | 366.8M |
| Operating Expenses | |||||
| R&D Expense | 17.9M | 16.3M | 18.1M | 12.6M | 1.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 201.9M | 202.5M | 218.6M | 214.3M | 162.6M |
| Selling & Marketing Expense | 182.7M | 177.3M | 182.5M | 178.0M | 138.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 413.6M | 404.2M | 420.1M | 396.5M | 300.2M |
| Cost and Expenses | 1.1B | 1.0B | 1.1B | 1.1B | 888.7M |
| Operating Income (EBIT) | 58.0M | 58.2M | 6.2M | 106.7M | 71.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 55.4M | 56.0M | 1.6M | 105.4M | 71.5M |
| Income Tax Expense | 27.1M | 29.6M | 36.9M | 47.6M | 39.4M |
| Bottom Line | |||||
| Net Income | 27.5M | 27.3M | (27.4M) | 63.6M | 32.6M |
| Earnings from Cont. Ops | 28.4M | 26.4M | (35.3M) | 57.8M | 32.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 27.5M | 27.3M | (27.4M) | 63.6M | 32.6M |
| Per Share | |||||
| Basic EPS | CN¥0.17 | CN¥0.17 | (CN¥0.17) | CN¥0.40 | CN¥0.22 |
| Diluted EPS | CN¥0.17 | CN¥0.17 | (CN¥0.17) | CN¥0.40 | CN¥0.22 |
| Revenue Per Share | CN¥7.00 | CN¥6.91 | CN¥6.93 | CN¥7.50 | CN¥6.45 |
| Shares | |||||
| Basic Shares Outstanding | 158.0M | 158.0M | 158.0M | 158.0M | 148.1M |
| Diluted Shares Outstanding | 158.0M | 158.0M | 158.0M | 158.0M | 148.1M |
| Profitability Metrics | |||||
| EBITDA | — | 142.3M | 98.1M | 187.5M | 144.9M |
| D&A | — | 84.1M | 91.9M | 80.8M | 73.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026